http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
韓光錄,尹德鎬,李仁政 湖西大學校工業技術硏究所 1999 工業技術硏究所論文集 Vol.18 No.-
In this paper, we implemented learning system and categorization system for categorizing internet documents. Learning system uses back propagation algorithm of neural network and, categorization system categorizes documents by using learning data from learning system. Web agent was used for retrieving documents from internet. We set 90 categories for learning and categorization. We evaluate the performance of learning and categorization system. Also, in this paper, we compare documents categorization performance to similarity measure of linear document vector.
성덕경,방경윤,오영륙,최은호,안일신,김옥경 한양대학교 이학기술연구소 2003 이학기술연구지 Vol.6 No.-
Spectroscopic ellipsometry 은 다양한 물질의 광학적 특징을 연구할 수 있는 강력한 기술이다. 현재 실리콘 웨이퍼 위의 박막 분석에는 그 효율성이 확실히 입증되어 있다. 그러나 현재 산업은 유리 기판위의 박막을 분석하기를 원하고 있다. Ellipsometry로 투명기판을 분석하기 위해서는 후면 반사에의한 비간섭성 효과를 고려해야 한다. 기존의 반사공식을 투명기판의 비간섭성을 고려하여 수정하였다. 투명기판 위의 샘플과 scratch를 낸 같은 샘플을 측정 분석하여 정확성을 확인하였다. 수정된 반사공식을 이용하면 디스플레이와 같은 투명재료를 이용하는 곳에 유용하게 사용될 것으로 기대되고 있다. A Spectroscpic ellipsometry is very strong technology to study optical properties of many materials. It has already substantiated a analytic efficiency about thin films above wafers to be made of silicon. However, the current industry needs thin films analyzed on a glass. When we analyze a glass using a ellipsometry, we have to consider a efficiency of incoherence due to reflect at the back side. So then, we slightly altered the original formula. We compared a scratched sample with a sample on the glass, because off getting a exactitude. Our technical development, using the changed formula, is expected the useful utilization in a part of using gIasses such as display.
강덕훈(Kang, Deok-Hun),송복득(Song, Bok-Deuk),신범주(Shin, Bum-Joo),이광호(Lee, Kwang-Ho),김진동(Kim, Jin-Dong),전계록(Jeon, Gye-Rok),왕수건(Wang, Soo-Geun) 한국산학기술학회 2010 한국산학기술학회논문지 Vol.11 No.4
미세증가감수지수 검사는 감각신경성난청의 세부 병변을 감별하기 위하여 사용되는 누가현상을 판별하는 검 사이다. 본 논문은 PC 기반 소프트웨어로 구현한 미세증가감수지수 검사 소프트웨어를 기술한다. 구현된 소프트웨어 는 검사자의 검사 참여 유·무에 따라 수동 검사와 자동 검사의 두 가지 모드를 제공함으로써 경제적인 검사가 진행 될 수 있게 한다. 또 필요할 경우에 자동으로 차폐를 수행한다. 그리고 1dB의 순간 상승음에 대한 검사뿐만 아니라 2dB와 5dB 상승음에 대한 검사도 지원함으로써 보다 정확한 검사 결과를 얻을 수 있도록 한다. SISI(Short Increment Sensitivity Index) test is to identify recruitment phenomenon that is used to diagnose detailed lesion of sensory-neural hearing loss. This paper describes SISI test software implemented to personal computer(PC). This software supports two test modes, consisting of auto-mode and manual-mode, which are classified according to whether or not audiologist to lead test, thereby enabling cost effective test. In addition, it has been designed to perform automatic masking in case of necessity. And by supporting not only 1dB increment but also 2 and 5dB increment, SISI test program of this paper makes it possible to acquire more accurate test result
증례 : 혈액종양 ; 일차성 중추신경계 림프종의 경막 내 Rituximab 치료 2예
장용호 ( Yong Ho Jang ),하태환 ( Tae Hwan Ha ),김덕희 ( Deok Hee Kim ),김성록 ( Sung Rok Kim ),유영진 ( Young Jin Yuh ),손병석 ( Byeong Seok Sohn ),이혜란 ( Hye Ran Lee ) 대한내과학회 2014 대한내과학회지 Vol.87 No.2
일차성 중추 신경계 림프종(PCNSL)은 완전 관해 이후에도 재발이 흔하고 대부분 뇌연수막 전이에 의해 불량한 예후를 나타내는데 rituximab 경막 내 투여를 통해 PCNSL의 안정 병변 기간 연장 및 부작용은 거의 나타나지 않은 임상증례 2례를 경험하여 보고하며 rituximab 경막 내 투여에 대한 임상 시험 및 연구가 좀 더 필요할 수 있겠다. Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin`s lymphoma (NHL), usually composed of diffuse large B-cells. Although rituximab is known for its curative effect on B-cell NHL, data on the use of intrathecal rituximab for PCNSL are limited. In this report, we present two patients showing relapsed PCNSL with lymphomatous meningitis. Both patients were refractory to conventional methotrexate-based intrathecal chemotherapy. However, after intrathecal rituximab with or without conventional intrathecal chemotherapy, both patients showed stable disease on magnetic resonance brain imaging and cerebrospinal fluid analysis. There were no serious adverse events during each of 3 and 6 cycles with intrathecal rituximab immunotherapy. (Korean J Med 2014;87:224-228)
Production of 8-hydroxydaidzein from soybean extract by Aspergillus oryzae KACC 40247.
Seo, Min-Ho,Kim, Bi-Na,Kim, Kyoung-Rok,Lee, Ki Won,Lee, Choong-Hwan,Oh, Deok-Kun Japan Society for Bioscience, Biotechnology, and A 2013 Bioscience, biotechnology, and biochemistry Vol.77 No.6
<P>Aspergillus oryzae KACC 40247 was selected from among 60 fungal strains as an effective 7,8,4'-trihydroxyisoflavone (8-hydroxydaidzein)-producing fungus. The optimal culture conditions for production by this strain in a 7-L fermentor were found to be 30 C, pH 6, and 300 rpm. Under these conditions, A. oryzae KACC 40247 produced 62 mg/L of 8-hydroxydaidzein from soybean extract in 30 h, with a productivity of 2.1 mg/L/h. These are the highest production and productivity for 8-hydroxydaidzein ever reported. To increase production, several concentrations of daidzin and of daidzein as precursor were added at several culture times. The optimal addition time and concentration for daidzin were 12 h and 1,248 mg/L, and those for daidzein were 12 h and 254 mg/L respectively. Maximum production and productivity for 8-hydroxydaidzein with the addition of daidzein were 95 mg/L and 3.2 mg/L/h respectively, and those with the addition of daidzin were 160 mg/L and 4.4 mg/L/h respectively.</P>
Seok Jin Kim,Young Rok Do,Ho-Sup Lee,Won-Sik Lee,Jee Hyun Kong,Jae-Yong Kwak,Hyeon-Seok Eom,Joon Ho Moon,Jun Ho Yi,Jeong-Ok Lee,Jae-Cheol Jo,Deok-Hwan Yang 대한혈액학회 2023 Blood Research Vol.58 No.4
Background Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. In Korea, BV has been approved for the treatment of relapsed or refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL), and cutaneous T-cell lymphomas, including mycosis fungoides (MF). However, there are limited data reflecting real-world experiences with BV treatment for HL, ALCL, and MF. Methods This was a multicenter, non-interventional registry study of the efficacy and safety of BV in patients with relapsed or refractory CD30-positive lymphoma (CISL1803/BRAVO). Outcomes were determined based on the occurrence of relapse or progression and overall survival after BV treatment. Results A total of 85 patients were enrolled in this study. The median number of BV cycles was 10 (range, 2‒16) in the patients with HL. The objective response rate (ORR) of patients with HL to BV was 85.4% (41/48), comprising 27 complete responses (CRs) and 14 partial responses (PRs). The ORR of ALCL was 88% (22/25), consisting of 17 CRs and five PRs, whereas the ORR of MF was 92% (11/12). At the median follow-up of 44.6 months after BV treatment, the median post-BV progression-free survival of HL, ALCL, and MF patients was 23.6 months, 29.0 months, and 16.7 months, respectively (P =0.641). The most common side effect of BV was peripheral neuropathy; 22 patients (25.9%, 22/85) experienced peripheral neuropathy (all grades). Conclusion The treatment outcomes of patients with relapsed or refractory CD30-positive lymphoma improved with BV treatment, and the safety profile was manageable.